Synergistic PXT3003 therapy uncouples neuromuscular function from dysmyelination in male Charcot–Marie–Tooth disease type 1A (CMT1A) rats - Prukop - 2020 - Journal of Neuroscience Research - Wiley Online Library
Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients | Clinical Research Trial Listing ( Charcot-Marie-Tooth Disease ) ( NCT04762758 )
Pharnext Raises 7.7M Euros to Support PXT3003 Development for CMT1A
Press Release: Pharnext provides regulatory and clinical update on PXT3003 Phase III study for the treatment of Charcot-Marie-Tooth Type 1A
Funding Supports Pharnext's Planned Phase 3 Trial of PXT3003 for CMT1A
PXT3003 - Twitter Search / Twitter
Interim Analysis from the Ongoing Open-Label Phase III
Response to PXT3003 on clinical scales (Full Analysis Set, n = 80).... | Download Scientific Diagram
Pivotal Phase 3 Trial of PXT3003 to Begin CMT1A Patient Enrollment Soon
BCL, NTX, SRB and their mix (PXT3003) down-regulate Pmp22 mRNA... | Download Scientific Diagram
A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot–Marie–Tooth type 1A | Orphanet Journal of Rare Diseases | Full Text
Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A) | PLOS ONE
Pharnext - PXT3003
Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A) | PLOS ONE
Synergistic PXT3003 therapy uncouples neuromuscular function from dysmyelination in male Charcot–Marie–Tooth disease type 1A (CMT1A) rats - Prukop - 2020 - Journal of Neuroscience Research - Wiley Online Library
Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A) | PLOS ONE
Pharnext - PXT3003
PDF) A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot–Marie–Tooth type 1A
Interim Analysis from the Ongoing Open-Label Phase III
Pharnext - PXT3003
PXT3003 therapy acting on Pmp22 overexpression and downstream... | Download Scientific Diagram
A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot–Marie–Tooth type 1A | Orphanet Journal of Rare Diseases | Full Text
An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A | Orphanet Journal of Rare Diseases
Run 4 CMT: Update Pharnext PXT 3003 Clinical Trial
A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot–Marie–Tooth type 1A | Orphanet Journal of Rare Diseases | Full Text
Synergistic PXT3003 therapy uncouples neuromuscular function from dysmyelination in male Charcot–Marie–Tooth disease type 1A (CMT1A) rats - Prukop - 2020 - Journal of Neuroscience Research - Wiley Online Library
Clinical Trials
